Status:

COMPLETED

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Lead Sponsor:

Genentech, Inc.

Conditions:

Multiple Myeloma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma. Cohorts of patients will receive multiple...

Eligibility Criteria

Inclusion

  • Adult patients; \>/= 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
  • Relapsed or refractory multiple myeloma for which no effective standard therapy exists
  • One of the prior therapies must have included a proteosome inhibitor or an immunomodulatory drug
  • Measurable disease as defined by protocol

Exclusion

  • Prior use of monoclonal antibody within 4 weeks before Cycle 1, Day 1
  • Treatment with radiotherapy, thalidomide, lenalidomide, bortezomib, any chemotherapeutic agent, or treatment with any investigational anti-cancer agent within 2 weeks prior to Cycle 1, Day 1
  • Toxicities from any previous treatment must be resolved prior to Cycle 1, Day 1, except for neuropathy
  • Completion of autologous stem cell transplant within 100 days prior to Cycle 1, Day 1
  • Prior allogeneic stem cell transplant
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
  • Grade \> 1 peripheral neuropathy
  • Active infection at screening or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to Cycle 1, Day 1
  • Positive for hepatitis B, hepatitis C or HIV infection
  • Pregnant or lactating women or women who intend to become pregnant within the period of time of this study

Key Trial Info

Start Date :

September 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2014

Estimated Enrollment :

39 Patients enrolled

Trial Details

Trial ID

NCT01432353

Start Date

September 1 2011

End Date

April 1 2014

Last Update

November 2 2016

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Scottsdale, Arizona, United States, 85259

2

Duarte, California, United States, 91010

3

Jacksonville, Florida, United States, 32224

4

Sarasota, Florida, United States, 34232